ArticleChemical biology & drug design2026
High-Throughput Platform for Discovery of Chemical Inhibitors of Heat Shock Protein 70 (Hsp70): Adaptation for the Specialized Bacterial HscA-HscB-IscU Complex.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Adenosine triphosphatases (ATPases) power essential cellular processes, but they commonly achieve full activity only within multi-protein assemblies, where cofactors and partner proteins tune their function. Yet, most high-throughput screening (HTS) campaigns that target ATPases tend to use highly purified enzymes without these important partners. Here we present a high-throughput platform for discovering small-molecule modulators of the bacterial heat shock protein (Hsp70) system: HscA-HscB-IscU, a promising anti-bacterial target. In this multi-protein complex, HscA has ATPase activity that is stimulated by HscB and IscU, such that inhibitors might act at either the enzyme active site or at protein-protein interactions (PPIs). To enable discovery of such molecules, we reconstituted purified HscA, HscB, and IscU, optimized their ratios to favor the active complex and then miniaturized a quinaldine red-based, phosphate detection assay to 384-well plates (Z' = 0.68). A pilot screen of ~2000 bioactive compounds identified 253 primary hits, suggesting an abnormally high hit rate (13.6%); however, many of these signals were attributable to compound insolubility and could be triaged using aggregation-detection strategies. Collectively, this workflow establishes a scalable platform for discovering chemical probes of the HscA-HscB-IscU system. More broadly, this work provides the foundation for HTS campaigns targeting reconstituted, multi-protein complexes containing ATPase activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.